FUKUOKA-CITY, Japan, Oct. 15,
2018 /PRNewswire/ -- Medical technology company Medmain Inc.
(https://medmain.net/) announced the alpha testing of its
ground-breaking, pathology diagnostic software: PidPort. PidPort
was originally developed in Japan
to enable precise and incredibly fast diagnosis of human body
pathologies of all types, with most diagnoses completed in less
than one minute. Medmain recently began testing the software in
hospital sites in Japan,
Thailand and Estonia.
Using AI, supercomputers, Deep Learning and original
image-processing technology, PidPort was developed to address gaps
found in diagnostic centers across the globe — a lack of
pathologists to meet testing volumes. This initial study of
PidPort's functionality will focus on stomach and colon
diagnostics. These areas were chosen because they represent the
largest percentage of organ testing currently ordered by physicians
in Japan.
PidPort has a variety of features which make it a useful option
for medical centers that experience large pathology testing volumes
or those that seek to augment their current pathology labs. With
PidPort:
- Results are incredibly quick, eliminating costly waits. Most
results can be outputted in just a single minute.
- Diagnoses can be performed at any hospital or secure location
in the world, eliminating the need for specialized labs while
reducing specimen travel or other storage concerns.
- Diagnostic results are delivered with a high degree of
accuracy, and can be implemented into a pathologist's work routine
efficiently.
- The software makes use of a system of virtual slides, allowing
it efficiency and the ability to handle a large volume of
data.
PidPort was also designed for simplicity of use and works with
its own proprietary image processing technology. Pathologists
import patient and pathology image data before running the images
and information through PidPort's specialized AI. PidPort then
gives a swift, clear diagnostic return back to the doctors in a
smooth, streamlined process.
To jointly develop PidPort, Medmain is in partnership with
esteemed medical institutions in both Japan and other countries. Medmain also
recently expanded its offices into the U.S. this past May, and
completed a successful one-million-dollar investment seed round in
July.
About Medmain Inc.
Medmain Inc. is a medical technology and utilization development
company that is comprised of technology experts, programmers and
medical professionals who partner with medical facilities across
the globe. In addition to its award-winning software and tech
solutions, Medmain also offers a dedicated cloud storage service
for university medical students called Medteria. Learn more at:
https://cloud.medmain.jp/lp_us/.
Contact:
Contact Information
Yuki Yoshida
Manager of Global Communication
+81-50-5236-5690
202345@email4pr.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/medmain-inc-set-to-begin-hospital-testing-trials-for-pidport-300730156.html
SOURCE Medmain Inc.